{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T14:23:46Z","timestamp":1768314226490,"version":"3.49.0"},"reference-count":36,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,5,15]],"date-time":"2025-05-15T00:00:00Z","timestamp":1747267200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>Alkylating agents and bevacizumab are both first-line chemotherapeutic options for the treatment of glioblastoma; however, their mechanisms of action differ substantially. This study aimed to compare the safety profiles of these two drug classes in the treatment of glioblastoma to inform clinical decision-making.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Adverse events reported between the first quarter of 2004 and the fourth quarter of 2023 were analyzed using data from the FDA Adverse Event Reporting System (FAERS) database. Disproportionality analysis was employed to assess and compare the AE signals associated with bevacizumab and alkylating agents.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>In the context of glioblastoma treatment, 3,323 adverse reports were associated with bevacizumab, 5,283 with temozolomide, and 427 with lomustine. The most frequently reported AEs for bevacizumab were fatigue (n = 276), hypertension (n = 220), and headache (n = 199). Compared to temozolomide, bevacizumab was more strongly associated with \u201cvascular disorders,\u201d \u201crenal and urinary disorders,\u201d and \u201chypertension.\u201d Notably, bevacizumab appeared to offer a potential safety advantage with respect to hematological adverse events.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Our analysis indicates that bevacizumab exhibits a distinct safety profile compared to alkylating agents, particularly demonstrating a lower incidence of hematological adverse events. Further prospective studies are warranted to validate these findings and to elucidate the underlying mechanisms responsible for the observed adverse events.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fphar.2025.1595642","type":"journal-article","created":{"date-parts":[[2025,5,15]],"date-time":"2025-05-15T10:14:27Z","timestamp":1747304067000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Comparative safety analysis of bevacizumab and alkylating agent in glioblastoma management \u2013 What have we learned recently?"],"prefix":"10.3389","volume":"16","author":[{"given":"Zhizhao","family":"Qu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiajia","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liu","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuanwei","family":"Fu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rui","family":"Bai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jinchuan","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongqin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,5,15]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1200\/JCO.22.00996","article-title":"Phase IIa study of SurVaxM plus adjuvant temozolomide for newly diagnosed glioblastoma","volume":"41","author":"Ahluwalia","year":"2023","journal-title":"JAMA Oncol."},{"key":"B2","unstructured":"Public summary document \u2013 may 2019 PBAC meeting\n          \n          \n          2019"},{"key":"B3","doi-asserted-by":"publisher","first-page":"5612","DOI":"10.1158\/1078-0432.CCR-14-0834","article-title":"Antiangiogenic therapy for glioblastoma: current status and future prospects","volume":"20","author":"Batchelor","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"B4","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1007\/s11060-020-03404-z","article-title":"Hypertension and proteinuria as clinical biomarkers of response to bevacizumab in glioblastoma patients","volume":"147","author":"Carvalho","year":"2020","journal-title":"J. Neurooncol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1007\/s12325-011-0007-3","article-title":"AVAglio: phase 3 trial of bevacizumab plus temozolomide and radiotherapy in newly diagnosed glioblastoma multiforme","volume":"28","author":"Chinot","year":"2011","journal-title":"Adv. Ther."},{"key":"B6","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1056\/NEJMoa1308345","article-title":"Bevacizumab plus radiotherapy\u2013temozolomide for newly diagnosed glioblastoma","volume":"370","author":"Chinot","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"B7","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1093\/neuonc\/noz232","article-title":"A randomized controlled phase III study of VB-111 combined with bevacizumab vs bevacizumab monotherapy in patients with recurrent glioblastoma (GLOBE)","volume":"22","author":"Cloughesy","year":"2020","journal-title":"Neuro Oncol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"v1","DOI":"10.1093\/neuonc\/nos218","article-title":"CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2005-2009","volume":"14","author":"Dolecek","year":"2012","journal-title":"Neuro Oncol."},{"key":"B9","article-title":"Avastin summary of product characteristics (SmPC)","year":"2017"},{"key":"B10","doi-asserted-by":"publisher","first-page":"4733","DOI":"10.1200\/JCO.2008.19.8721","article-title":"Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma","volume":"27","author":"Friedman","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1186\/s12885-023-11043-6","article-title":"Use of Bevacizumab in recurrent glioblastoma: a scoping review and evidence map","volume":"23","author":"Fu","year":"2023","journal-title":"BMC Cancer"},{"key":"B12","doi-asserted-by":"publisher","first-page":"470","DOI":"10.3390\/ph13120470","article-title":"Update on chemotherapeutic approaches and management of bevacizumab usage for glioblastoma","volume":"13","author":"Funakoshi","year":"2020","journal-title":"Pharm. (Basel)"},{"key":"B13","doi-asserted-by":"publisher","first-page":"102017","DOI":"10.1016\/j.ctrv.2020.102017","article-title":"Bevacizumab (Avastin\u00ae) in cancer treatment: a review of 15\u00a0years of clinical experience and future outlook","volume":"86","author":"Garcia","year":"2020","journal-title":"Cancer Treat. Rev."},{"key":"B14","article-title":"Bevacizumab","volume-title":"StatPearls","author":"Gerriets","year":"2025"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1200\/JCO.2005.06.081","article-title":"Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis","volume":"23","author":"Hicklin","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"e29269","DOI":"10.7759\/cureus.29269","article-title":"Bevacizumab-induced hypertension as a potential physiological clinical biomarker for improved outcomes in patients with recurrent glioblastoma multiforme: a systematic review","volume":"14","author":"Khan","year":"2022","journal-title":"Cureus"},{"key":"B18","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1200\/JCO.2008.16.3055","article-title":"Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma","volume":"27","author":"Kreisl","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/j.gendis.2016.04.007","article-title":"Temozolomide resistance in glioblastoma multiforme","volume":"3","author":"Lee","year":"2016","journal-title":"Genes Dis."},{"key":"B20","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/j.clcc.2018.01.011","article-title":"A multicenter clinical phase II study of FOLFOXIRI plus bevacizumab as first-line therapy in patients with metastatic colorectal cancer: QUATTRO study","volume":"17","author":"Oki","year":"2018","journal-title":"Clin. Colorectal Cancer"},{"key":"B15","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1093\/neuonc\/noac099","article-title":"Radiotherapy combined with nivolumab or temozolomide for newly diagnosed glioblastoma with unmethylated MGMT promoter: an international randomized phase III trial","volume":"25","author":"Omuro","year":"2023","journal-title":"Neuro Oncol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"iv73","DOI":"10.1093\/neuonc\/nos197","article-title":"Thromboembolic disease in patients with high-grade glioma","volume":"14","author":"Perry","year":"2012","journal-title":"Neuro Oncol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"701","DOI":"10.7554\/eLife.52176","article-title":"Understanding the immunosuppressive microenvironment of glioma: mechanistic insights and therapeutic opportunities","volume":"20","author":"Pombo Antunes","year":"2020","journal-title":"Nat. Rev. Cancer."},{"key":"B23","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1001\/jama.2011.51","article-title":"Treatment-related mortality with bevacizumab in cancer patients: a meta-analysis","volume":"305","author":"Ranpura","year":"2011","journal-title":"JAMA"},{"key":"B24","doi-asserted-by":"publisher","first-page":"7207","DOI":"10.3390\/ijms23137207","article-title":"Glioblastoma treatment: state-of-the-art and future perspectives","volume":"23","author":"Rodriguez-Camacho","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"B25","unstructured":"2024"},{"key":"B26","doi-asserted-by":"publisher","first-page":"4127","DOI":"10.1200\/JCO.2007.11.8554","article-title":"Chemoradiotherapy in malignant glioma: standard of care and future directions","volume":"25","author":"Stupp","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"2306","DOI":"10.1001\/jama.2017.18718","article-title":"Effect of tumor-treating fields plus maintenance temozolomide vs maintenance temozolomide alone on survival in patients with glioblastoma: a randomized clinical trial","volume":"318","author":"Stupp","year":"2017","journal-title":"JAMA"},{"key":"B28","doi-asserted-by":"publisher","first-page":"299","DOI":"10.3322\/caac.21613","article-title":"Management of glioblastoma: state of the art and future directions","volume":"70","author":"Tan","year":"2020","journal-title":"CA Cancer J. Clin."},{"key":"B29","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1080\/14740338.2023.2248876","article-title":"A pharmacovigilance study of adverse event profiles and haemorrhagic safety of bevacizumab based on the FAERS database","volume":"23","author":"Tang","year":"2024","journal-title":"Expert Opin. Drug Saf."},{"key":"B30","article-title":"Avastin US prescribing information (USPI)","year":""},{"key":"B31","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1007\/s00280-011-1679-8","article-title":"Hematologic adverse events associated with temozolomide","volume":"69","author":"Villano","year":"2012","journal-title":"Cancer Chemother. Pharmacol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1093\/neuonc\/noab011","article-title":"Neurocognitive, symptom, and health-related quality of life outcomes of a randomized trial of bevacizumab for newly diagnosed glioblastoma (NRG Oncology\/RTOG 0825)","volume":"23","author":"Wefel","year":"2021","journal-title":"Neuro Oncol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"102029","DOI":"10.1016\/j.ctrv.2020.102029","article-title":"How did lomustine become standard of care in recurrent glioblastoma?","volume":"87","author":"Weller","year":"2020","journal-title":"Cancer Treat. Rev."},{"key":"B34","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1056\/NEJMoa021491","article-title":"A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer","volume":"349","author":"Yang","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"B35","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1016\/j.jaip.2020.09.021","article-title":"Emerging causes of drug-induced anaphylaxis: a review of anaphylaxis-associated reports in the FDA adverse event reporting system (FAERS)","volume":"9","author":"Yu","year":"2021","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"B36","doi-asserted-by":"publisher","first-page":"1437436","DOI":"10.3389\/fphar.2024.1437436","article-title":"Comprehensive understanding of the adverse effects associated with temozolomide: a disproportionate analysis based on the FAERS database","volume":"15","author":"Zhou","year":"2024","journal-title":"Front. Pharmacol."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1595642\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,15]],"date-time":"2025-05-15T10:14:29Z","timestamp":1747304069000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1595642\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,15]]},"references-count":36,"alternative-id":["10.3389\/fphar.2025.1595642"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2025.1595642","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,15]]},"article-number":"1595642"}}